ClinicalTrials.gg
CompletedNCT02798211Updated Oct 7, 2021Results posted

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

A Phase 4 interventional study of Secukinumab 300 mg and Secukinumab 150 mg in Psoriatic Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 58 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing secukinumab in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. secukinumab · Arthritis, Psoriatic.

Enrollment
13th of 26
258 · median 231
Started
2016
with 4 others
Phase 4
4 of 26
none open now
Registered
16th of 26
by date
Lead sponsor
17 of 26
Novartis Pharmaceuticals

Among the 26 studies testing secukinumab in Arthritis, Psoriatic, this one is the 13th largest by enrollment, is one of 5 that started in 2016, is one of 4 in phase 4, and was the 16th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 26 studies testing secukinumab in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing secukinumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

To demonstrate that the efficacy of secukinumab 300 mg at Week 16 was superior to placebo in adult patients with active PsA based on the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response.

Read the detailed description

Treatment Period 1 was defined as the period from Randomization through Week 16 (prior to the Week 16 dose). At the start of placebo-controlled Treatment Period 1, patients were randomized via Interactive Response Technology (IRT) in a 2:2:1 ratio to 1 of 3 treatment groups.

Group 1- Secukinumab 300 mg: secukinumab 300 mg (2 s.c. injections of the 150-mg dose) once weekly for 5 weeks (at Baseline, Weeks 1, 2, 3, and 4), followed by dosing every 4 weeks.

Group 2- Secukinumab 150 mg: secukinumab 150 mg (1 s.c. injection of the 150-mg dose and 1 s.c. injection of placebo) once weekly for 5 weeks (at Baseline, Weeks 1, 2, 3, and 4), followed by dosing every 4 weeks.

Group 3- Placebo: placebo (2 s.c. injections of 150 mg secukinumab placebo per dose) once per week for 5 weeks (at Baseline, Weeks 1, 2, 3, and 4), followed by dosing every 4 weeks.

At each study treatment visit 2 s.c. injections in the form of prefilled syringes (PFS) were administered. This was necessary to maintain the blind, as secukinumab in PFS is available in either 1.0 mL (150 mg) or 2 x 1.0 mL (300 mg). Placebo to secukinumab was also available in 1.0 mL to match the active drug.

Rescue medication was not allowed before completion of Week 16 assessments.

Treatment Period 2 patients receiving secukinumab 300 mg (Group 1) continued to receive the same dose up to Week 48.

At Weeks 16, 28, and 40 patients on secukinumab 150 mg (Group 2) were classified as responders (≥20% improvement from BL in both tender and swollen joint counts) or nonresponders.

  • At Weeks 16, 28, and 40 patients on secukinumab 150 mg (Group 2) who were responders continued to receive secukinumab 150 mg (1.0 mL) plus placebo (1.0 mL) every 4 weeks until next evaluation of responder status at Weeks 28 or 40.
  • Patients who did not meet the responder criteria at Week 16, 28, or 40 started receiving secukinumab 300 mg s.c. every 4 weeks and continued this dose up to Week 48.
  • Patients on placebo (Group 3) regardless of their responder status started receiving secukinumab 300 mg s.c. every 4 weeks from Week 16 up to Week 48.
03

Conditions studied

  • Psoriatic Arthritis

Keywords

  • PsA
  • ACR
  • CASPAR
  • inflammatory arthritis
  • spondylitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant, non-lactating female patients at least 18 years of age
  • Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6 months with moderate to severe PsA who must have at Baseline ≥3 tender joints out of 78 and ≥3 swollen out of 76 (dactylitis of a digit counts as one joint each)
  • Rheumatoid factor and/or anti-CCP antibodies negative at screening
  • A target skin psoriatic lesion and a PASI score of 1 or greater

Exclusion criteria

Exclusion Criteria:

  • Chest X-ray with evidence of ongoing infectious or malignant process
  • Patients who ever received biologic immunomodulating agents including those targeting TNFα, IL-6 and IL-12/23 or approved
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
258 participants (actual)

Study arms

  • Active comparator
    Group 1

    secukinumab 300mg s.c. injection

    Drug: Secukinumab 300 mg

  • Active comparator
    Group 2

    secukinumab 150 mg s.c. injection

    Drug: Secukinumab 150 mg

  • Placebo comparator
    Group 3

    Placebo s.c. injection

    Other: Placebo

Interventions

  • 150 mg x 2 s.c. injection

    Also known as: AIN457

  • 150 mg s.c. injection

    Also known as: AIN457

  • OtherPlacebo

    Placebo

    Also known as: s.c. injection

06

What researchers measure

Primary outcomes

  1. Percent of Patients Achieving American College of Rheumatology Score of at Least 20% (ACR20) Response Criteria on Secukinumab 300 mg and 150 mg vs. Placebo at Week 16

    A patient was considered as improved according to the ACR20 criteria if she/he had at least 20% improvement in two of the following measures:Tender joint count, Swollen joint count and at least 3 of the following 5 measures: Patient's assessment of pain, Patient's global assessment disease activity, Physician's global assessment of disease activity, Health Assessment Questionnaire (HAQ©) score,Acute phase reactant (hsCRP or ESR). Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.

    Time frame: 16 Weeks

Secondary outcomes

  1. Percentage of Patients With Dactylitis in the Subset of Subjects Who Have Dactylitis at Week 16

    The percent of patients in the Dactylitis Subset with dactylitis in the secukinumab 300 mg group at Week 16. Dactylitis is severe inflammation of the finger and toe joints. Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.

    Time frame: Week 16

  2. Percentage of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Baseline (SPARCC) at Week 16

    Enthesitis, also called enthesopathy, is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.

    Time frame: 16 Weeks

  3. Percentage of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Week 16 (LEI)

    Enthesitis, also called enthesopathy, is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. LEI=Leeds Enthesitis Index

    Time frame: 16 Weeks

  4. Percentage of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Week 16 (Combined SPARCC and LEI)

    Statistical analysis (logistic regression) of presence of enthesitis (Combined SPARCC and LEI) by visit - in treatment period 1 (non-responder imputation) (Combined SPARCC and LEI Subset) Enthesitis, also called enthesopathy, is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.

    Time frame: 16 Weeks

  5. Percentage of Patients Achieving ACR50 Response Criteria on Secukinumab 300 or 150 mg vs. Placebo at Week 16

    A patient was considered as improved according the ACR50 criteria if she/he had at least 50% improvement in the two of the following measures: Tender joint count, Swollen joint count and at least 3 of the following 5 measures: Patient's assessment of pain, Patient's global assessment disease activity,Physician's global assessment of disease activity, Health Assessment Questionnaire (HAQ©) score,Acute phase reactant (hsCRP or ESR) Statistical analysis (logistic regression) of ACR50 response by visit - in treatment period 1 (non-responder imputation) (Full Analysis Set) Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.

    Time frame: 16 Weeks

  6. Percentage of Patients Achieving ACR70 Response Criteria on Secukinumab 300 or 150 mg vs. Placebo at Week 16

    A patient was considered as improved according the ACR70 criteria if she/he had at least 70% improvement in the two of the following measures: Tender joint count, Swollen joint count and at least 3 of the following 5 measures: Patient's assessment of pain, Patient's global assessment disease activity,Physician's global assessment of disease activity, Health Assessment Questionnaire (HAQ©) score,Acute phase reactant (hsCRP or ESR) Statistical analysis (logistic regression) of ACR70 response by visit - in treatment period 1 (non-responder imputation) Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.

    Time frame: 16 Weeks

  7. Percentage of Patients Achieving a PASI75 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Week 16

    A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is above the current benchmark of primary endpoints for most clinical trials with endpoints of psoriasis.

    Time frame: 16 Weeks

  8. Percentage of Patients Achieving a PASI90 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Week 16

    A 90% reduction in the Psoriasis Area and Severity Index score (PASI 90) is above the current benchmark of primary endpoints for most clinical trials with endpoints of psoriasis.

    Time frame: 16 Weeks

  9. Percentage of Patients Achieving a PASI100 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Week 16

    A 100% reduction in the Psoriasis Area and Severity Index score (PASI 100) is above the current benchmark of primary endpoints for most clinical trials with endpoints of psoriasis. Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.

    Time frame: 16 Weeks

  10. Change From Baseline to Week 16 in DAS28-CRP

    DAS-CRP uses the C-Reactive Protein (CRP) value. Disease Activity Score (DAS28-CRP) values range from 2.0 to 10.0 while higher values mean a higher disease activity. A DAS28-CRP below the value of 2.6 is interpreted as Remission. DAS28-CRP uses 28 different joints for its calculation: proximal interphalangeal joints (10 joints) metacarpophalangeal joints (10) wrists (2) elbows (2) shoulders (2) knees (2) With the above mentioned parameters. Least squares mean (LSM), Least squares mean (LSM) treatment difference, 95% confidence interval (CI) for treatment difference, and p-values are from an analysis of covariance (ANCOVA) model with treatment (3 treatment groups), baseline DAS28-CRP score, methotrexate usage at baseline (yes, no), and body weight(kg) as explanatory variables.

    Time frame: baseline, 16 weeks

  11. Change From Baseline to Week 16 in HAQ-DI

    The Health assessment questionnaire disability index (HAQ-DI) is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). The average score across the functional areas yields an overall HAQ score which ranges from 0 (no disability) to 3 (completely disabled).

    Time frame: 16 Weeks

Other outcomes

  1. Number and Percentage of Patients With ACR20 Response by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)

    Exploratory The ACR20 is a composite measure defined as both improvement of 20% in the number of tender and number of swollen joints, and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP)

    Time frame: up to 52 weeks

  2. Number and Percentage of Patients With ACR50, ACR70 Response by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)

    Exploratory

    Time frame: up to 52 weeks

  3. Number and Percentage of Patients With Presence of Dactylitis by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)

    Exploratory

    Time frame: up to 52 weeks

  4. Number and Percentage of Patients With Presence of Enthesitis by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)

    Exploratory

    Time frame: up to 52 weeks

  5. Number and Percentage of Patients With Minimal Disease Activity Response by Visit in Entire Treatment Period (up to Week 52) (Non-responder Imputation)

    Exploratory

    Time frame: up to 52 weeks

  6. Number and Percentage of Patients With PASI75, PASI90 and PASI100 Response by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)

    Exploratory

    Time frame: up to 52 weeks

07

Results

Posted Jan 28, 2021
Limitations and caveats
Period 2 (week 16 up to 52 weeks) contained only exploratory outcomes. AEs are presented cumulitively

Participant flow

Of 349 patients screened for the study, 271 passed screening and 258 were randomized (103 to secukinumab 300 mg, 103 to secukinumab 150 mg, and 52 to placebo). A higher percentage of patients in the secukinumab 300 mg group completed Period 1 (94.2%) than in the secukinumab 150 mg (90.3%) or placebo (88.5%) groups.

Period 1
Participant flow — Period 1
MilestoneGroup 1Group 2Group 3Group 4Group 5Group 6
Started10310352000
Completed979346000
Not completed6106000
Withdrew: Adverse event110000
Withdrew: Lost to follow-up210000
Withdrew: Protocol violation002000
Withdrew: Withdrawal by subject110000
Withdrew: Death001000
Withdrew: Withdrawal of informed consent273000
Period 2
Participant flow — Period 2
MilestoneGroup 1Group 2Group 3Group 4Group 5Group 6
Started9700504246
Completed8300433440
Not completed1400786
Withdrew: Withdrawal by subject200022
Withdrew: Adverse event500010
Withdrew: Lack of efficacy100101
Withdrew: Lost to follow-up300020
Withdrew: Physician decision100110
Withdrew: Pregnancy000200
Withdrew: Technical problems100100
Withdrew: Withdrawal of informed consent100223

Outcome measures

PrimaryPercent of Patients Achieving American College of Rheumatology Score of at Least 20% (ACR20) Response Criteria on Secukinumab 300 mg and 150 mg vs. Placebo at Week 16

A patient was considered as improved according to the ACR20 criteria if she/he had at least 20% improvement in two of the following measures:Tender joint count, Swollen joint count and at least 3 of the following 5 measures: Patient's assessment of pain, Patient's global assessment disease activity, Physician's global assessment of disease activity, Health Assessment Questionnaire (HAQ©) score,Acute phase reactant (hsCRP or ESR). Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.

Time frame:
16 Weeks
Reported as:
Number · percentage of participants
Percent of Patients Achieving American College of Rheumatology Score of at Least 20% (ACR20) Response Criteria on Secukinumab 300 mg and 150 mg vs. Placebo at Week 16
percentage of participantsGroup 1Group 2Group 3
Percent of Patients Achieving American College of Rheumatology Score of at Least 20% (ACR20) Response Criteria on Secukinumab 300 mg and 150 mg vs. Placebo at Week 1651.4636.8923.08
Statistical analysis
  • Group 1 vs Group 2 · Regression, Logistic · p = 0.0011 · Odds ratio (or): 3.51 · 95% CI 1.65 to 7.45Statistical analysis (logistic regression) of ACR20 response in treatment period 1 (non-responder imputation)
  • Group 2 · Regression, Logistic · p = 0.0961 · Odds ratio (or): 1.92 · 95% CI 0.89 to 4.15Statistical analysis (logistic regression) of ACR20 response in treatment period 1 (non-responder imputation)
SecondaryPercentage of Patients With Dactylitis in the Subset of Subjects Who Have Dactylitis at Week 16

The percent of patients in the Dactylitis Subset with dactylitis in the secukinumab 300 mg group at Week 16. Dactylitis is severe inflammation of the finger and toe joints. Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.

Time frame:
Week 16
Reported as:
Number · percent of participants
Percentage of Patients With Dactylitis in the Subset of Subjects Who Have Dactylitis at Week 16
percent of participantsGroup 1Group 2Group 3
Percentage of Patients With Dactylitis in the Subset of Subjects Who Have Dactylitis at Week 1653.0644.2365.22
Statistical analysis
  • Group 1 · Regression, Logistic · p = 0.3330 · Odds ratio (or): 0.60 · 95% CI 0.22 to 1.68Statistical analysis (logistic regression) of presence of dactylitis by visit in treatment period 1 (non-responder imputation)
  • Group 2 · Regression, Logistic · p = 0.0841 · Odds ratio (or): 0.40 · 95% CI 0.14 to 1.13Statistical analysis (logistic regression) of presence of dactylitis in treatment period 1 (non-responder imputation)
SecondaryPercentage of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Baseline (SPARCC) at Week 16

Enthesitis, also called enthesopathy, is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.

Time frame:
16 Weeks
Reported as:
Number · percentage of participants
Percentage of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Baseline (SPARCC) at Week 16
percentage of participantsGroup 1Group 2Group 3
Percentage of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Baseline (SPARCC) at Week 1663.8957.8976.92
Statistical analysis
  • Group 1 · Regression, Logistic · p = 0.1618 · Odds ratio (or): 0.52 · 95% CI 0.21 to 1.30Statistical analysis (logistic regression) of presence of enthesitis (SPARCC) in treatment period 1 (non-responder imputation)
  • Group 2 · Regression, Logistic · p = 0.0898 · Odds ratio (or): 0.46 · 95% CI 0.19 to 1.13Statistical analysis (logistic regression) of presence of enthesitis (SPARCC) in treatment period 1 (non-responder imputation)
SecondaryPercentage of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Week 16 (LEI)

Enthesitis, also called enthesopathy, is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. LEI=Leeds Enthesitis Index

Time frame:
16 Weeks
Reported as:
Number · percentage of participants
Percentage of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Week 16 (LEI)
percentage of participantsGroup 1Group 2Group 3
Percentage of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Week 16 (LEI)56.0652.2482.35
Statistical analysis
  • Group 1 · Regression, Logistic · p = 0.0125 · Odds ratio (or): 0.27 · 95% CI 0.09 to 0.75Statistical analysis (logistic regression) of presence of enthesitis (LEI) in treatment period 1 (non-responder imputation)
  • Group 2 · Regression, Logistic · p = 0.0086 · Odds ratio (or): 0.25 · 95% CI 0.09 to 0.70Statistical analysis (logistic regression) of presence of enthesitis (SPARCC) in treatment period 1 (non-responder imputation)
SecondaryPercentage of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Week 16 (Combined SPARCC and LEI)

Statistical analysis (logistic regression) of presence of enthesitis (Combined SPARCC and LEI) by visit - in treatment period 1 (non-responder imputation) (Combined SPARCC and LEI Subset) Enthesitis, also called enthesopathy, is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.

Time frame:
16 Weeks
Reported as:
Number · percentage of participants
Percentage of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Week 16 (Combined SPARCC and LEI)
percentage of participantsGroup 1Group 2Group 3
Percentage of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Week 16 (Combined SPARCC and LEI)62.1659.2182.05
Statistical analysis
  • Group 1 · Regression, Logistic · p = 0.0338 · Odds ratio (or): 0.35 · 95% CI 0.13 to 0.92Statistical analysis (logistic regression) of presence of enthesitis (SPARCC and LEI) in treatment period 1 (non-responder imputation)
  • Group 2 · Regression, Logistic · p = 0.0359 · Odds ratio (or): 0.36 · 95% CI 0.14 to 0.93Statistical analysis (logistic regression) of presence of enthesitis (SPARCC and LEI) in treatment period 1 (non-responder imputation)
SecondaryPercentage of Patients Achieving ACR50 Response Criteria on Secukinumab 300 or 150 mg vs. Placebo at Week 16

A patient was considered as improved according the ACR50 criteria if she/he had at least 50% improvement in the two of the following measures: Tender joint count, Swollen joint count and at least 3 of the following 5 measures: Patient's assessment of pain, Patient's global assessment disease activity,Physician's global assessment of disease activity, Health Assessment Questionnaire (HAQ©) score,Acute phase reactant (hsCRP or ESR) Statistical analysis (logistic regression) of ACR50 response by visit - in treatment period 1 (non-responder imputation) (Full Analysis Set) Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.

Time frame:
16 Weeks
Reported as:
Number · percentage of participants
Percentage of Patients Achieving ACR50 Response Criteria on Secukinumab 300 or 150 mg vs. Placebo at Week 16
percentage of participantsGroup 1Group 2Group 3
Percentage of Patients Achieving ACR50 Response Criteria on Secukinumab 300 or 150 mg vs. Placebo at Week 1628.1624.275.77
Statistical analysis
  • Group 1 · Regression, Logistic · p = 0.0038 · Odds ratio, log: 6.30 · 95% CI 1.81 to 21.88Statistical analysis (logistic regression) of ACR50 response in treatment period 1 (non-responder imputation)
  • Group 2 · Regression, Logistic · p = 0.0149 · Odds ratio (or): 4.77 · 95% CI 1.36 to 16.77Statistical analysis (logistic regression) of ACR50 response by visit in treatment period 1 (non-responder imputation)
SecondaryPercentage of Patients Achieving ACR70 Response Criteria on Secukinumab 300 or 150 mg vs. Placebo at Week 16

A patient was considered as improved according the ACR70 criteria if she/he had at least 70% improvement in the two of the following measures: Tender joint count, Swollen joint count and at least 3 of the following 5 measures: Patient's assessment of pain, Patient's global assessment disease activity,Physician's global assessment of disease activity, Health Assessment Questionnaire (HAQ©) score,Acute phase reactant (hsCRP or ESR) Statistical analysis (logistic regression) of ACR70 response by visit - in treatment period 1 (non-responder imputation) Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.

Time frame:
16 Weeks
Reported as:
Number · percentage of participants
Percentage of Patients Achieving ACR70 Response Criteria on Secukinumab 300 or 150 mg vs. Placebo at Week 16
percentage of participantsGroup 1Group 2Group 3
Percentage of Patients Achieving ACR70 Response Criteria on Secukinumab 300 or 150 mg vs. Placebo at Week 1617.4810.681.92
Statistical analysis
  • Group 1 · Regression, Logistic · p = 0.0243 · Odds ratio, log: 10.50 · 95% CI 1.36 to 81.30Statistical analysis (logistic regression) of ACR70 response in treatment period 1 (non-responder imputation)
  • Group 2 · Regression, Logistic · p = 0.1120 · Odds ratio (or): 5.42 · 95% CI 0.67 to 43.64Statistical analysis (logistic regression) of ACR70 response by visit in treatment period 1 (non-responder imputation)
SecondaryPercentage of Patients Achieving a PASI75 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Week 16

A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is above the current benchmark of primary endpoints for most clinical trials with endpoints of psoriasis.

Time frame:
16 Weeks
Reported as:
Number · percentage of participants
Percentage of Patients Achieving a PASI75 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Week 16
percentage of participantsGroup 1Group 2Group 3
Percentage of Patients Achieving a PASI75 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Week 1664.5654.2216.28
Statistical analysis
  • Group 1 · Regression, Logistic · p = <0.0001 · Odds ratio, log: 9.49 · 95% CI 3.73 to 24.16Statistical analysis (logistic regression) of PASI75 response by visit in treatment period 1 (non-responder imputation)
  • Group 2 · Regression, Logistic · p = 0.0001 · Odds ratio (or): 6.38 · 95% CI 2.51 to 16.24Statistical analysis (logistic regression) of PASI75 response by visit - in treatment period 1 (non-responder imputation)
SecondaryPercentage of Patients Achieving a PASI90 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Week 16

A 90% reduction in the Psoriasis Area and Severity Index score (PASI 90) is above the current benchmark of primary endpoints for most clinical trials with endpoints of psoriasis.

Time frame:
16 Weeks
Reported as:
Number · percentage of participants
Percentage of Patients Achieving a PASI90 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Week 16
percentage of participantsGroup 1Group 2Group 3
Percentage of Patients Achieving a PASI90 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Week 1649.3736.149.3
Statistical analysis
  • Group 1 · Regression, Logistic · p = <.0001 · Odds ratio, log: 9.86 · 95% CI 3.19 to 30.45Statistical analysis (logistic regression) of PASI90 response in treatment period 1 (non-responder imputation)
  • Group 2 · Regression, Logistic · p = 0.0043 · Odds ratio (or): 5.21 · 95% CI 1.68 to 16.21Statistical analysis (logistic regression) of PASI90 response in treatment period 1 (non-responder imputation)
SecondaryPercentage of Patients Achieving a PASI100 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Week 16

A 100% reduction in the Psoriasis Area and Severity Index score (PASI 100) is above the current benchmark of primary endpoints for most clinical trials with endpoints of psoriasis. Odds ratio, 95% confidence interval for odds ratio, and p-value are from a logistic regression model with treatment (3 treatment groups), methotrexate usage at baseline (yes, no) and body weight (kg) as explanatory variables.

Time frame:
16 Weeks
Reported as:
Number · percentage of participants
Percentage of Patients Achieving a PASI100 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Week 16
percentage of participantsGroup 1Group 2Group 3
Percentage of Patients Achieving a PASI100 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Week 1625.3218.072.33
Statistical analysis
  • Group 1 · Regression, Logistic · p = 0.0107 · Odds ratio, log: 14.38 · 95% CI 1.86 to 111.53Statistical analysis (logistic regression) of PASI100 response by visit in treatment period 1 (non-responder imputation)
  • Group 2 · Regression, Logistic · p = 0.0307 · Odds ratio (or): 9.82 · 95% CI 1.24 to 77.90Statistical analysis (logistic regression) of PAS100 response by in treatment period 1 (non-responder imputation)
SecondaryChange From Baseline to Week 16 in DAS28-CRP

DAS-CRP uses the C-Reactive Protein (CRP) value. Disease Activity Score (DAS28-CRP) values range from 2.0 to 10.0 while higher values mean a higher disease activity. A DAS28-CRP below the value of 2.6 is interpreted as Remission. DAS28-CRP uses 28 different joints for its calculation: proximal interphalangeal joints (10 joints) metacarpophalangeal joints (10) wrists (2) elbows (2) shoulders (2) knees (2) With the above mentioned parameters. Least squares mean (LSM), Least squares mean (LSM) treatment difference, 95% confidence interval (CI) for treatment difference, and p-values are from an analysis of covariance (ANCOVA) model with treatment (3 treatment groups), baseline DAS28-CRP score, methotrexate usage at baseline (yes, no), and body weight(kg) as explanatory variables.

Time frame:
baseline, 16 weeks
Reported as:
Least squares mean · scores on a scale
Change From Baseline to Week 16 in DAS28-CRP
scores on a scaleGroup 1Group 2Group 3
Change From Baseline to Week 16 in DAS28-CRP-1.39 ± 0.120-1.18 ± 0.125-0.35 ± 0.170
Statistical analysis
  • Group 1 · ANCOVA · p = <.0001 · Ls mean of treatment difference: -1.05 · 95% CI -1.45 to -0.65Statistical analysis (ANCOVA) of change from baseline in DAS28-CRP score in treatment period 1 (LOCF)
  • Group 2 · ANCOVA · p = <.0001 · Ls means of treatment difference: -0.83 · 95% CI -1.24 to -0.43Statistical analysis (ANCOVA) of change from baseline in DAS28-CRP score in treatment period 1 (LOCF)
SecondaryChange From Baseline to Week 16 in HAQ-DI

The Health assessment questionnaire disability index (HAQ-DI) is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). The average score across the functional areas yields an overall HAQ score which ranges from 0 (no disability) to 3 (completely disabled).

Time frame:
16 Weeks
Reported as:
Least squares mean · scores on a scale
Change From Baseline to Week 16 in HAQ-DI
scores on a scaleGroup 1Group 2Group 3
Change From Baseline to Week 16 in HAQ-DI-0.32 (-0.37 to -0.05)-0.24 (-0.30 to 0.03)-0.11 (NA to NA)
Statistical analysis
  • Group 1 · ANCOVA · p = 0.0107 · Ls mean of treatment difference: -0.21 · 95% CI -0.37 to -0.05Statistical analysis (ANCOVA) of change from baseline in HAQ-DI score by in treatment period 1 (LOCF)
  • Group 2 · ANCOVA · p = 0.1109 · Ls mean treatment difference: -0.13 · 95% CI -0.30 to 0.03Statistical analysis (ANCOVA) of change from baseline in HAQ-DI score by visit - in treatment period 1 (LOCF)
Other pre-specifiedNumber and Percentage of Patients With ACR20 Response by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)

Exploratory The ACR20 is a composite measure defined as both improvement of 20% in the number of tender and number of swollen joints, and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP)

Time frame:
up to 52 weeks
Reported as:
Number · percentage of participants
Number and Percentage of Patients With ACR20 Response by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)
percentage of participantsGroup 1Group 2Group 3Group 4Group 5
week 117.488.004.765.831.92
week 1651.4672.004.7636.8923.08
week 5247.5768.0028.5744.6642.31
Other pre-specifiedNumber and Percentage of Patients With ACR50, ACR70 Response by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)

Exploratory

Time frame:
up to 52 weeks
Reported as:
Number · percentage of participants
Number and Percentage of Patients With ACR50, ACR70 Response by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)
percentage of participantsGroup 1Group 2Group 3Group 4Group 5
ACR50 - week 12.91—2.38.97—
ACR50 - week 1628.1646.004.7624.275.77
ACR70 - week 1617.4822.00—10.681.92
ACR50 - week 5232.0448.0014.2929.1317.31
ACR70 - week 5221.3628.004.7615.535.77
Other pre-specifiedNumber and Percentage of Patients With Presence of Dactylitis by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)

Exploratory

Time frame:
up to 52 weeks
Reported as:
Number · percentage of participants
Number and Percentage of Patients With Presence of Dactylitis by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)
percentage of participantsGroup 1Group 2Group 3Group 4Group 5
week 142.7242.0035.7140.7832.69
week 1625.2424.0026.1922.3328.85
week 5210.686.0011.907.779.62
Other pre-specifiedNumber and Percentage of Patients With Presence of Enthesitis by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)

Exploratory

Time frame:
up to 52 weeks
Reported as:
Number · percentage of participants
Number and Percentage of Patients With Presence of Enthesitis by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)
percentage of participantsGroup 1Group 2Group 3Group 4Group 5
week 184.8566.6788.8977.6179.41
week 1656.0624.2477.7852.2482.35
week 5253.0336.3666.6753.7361.76
Other pre-specifiedNumber and Percentage of Patients With Minimal Disease Activity Response by Visit in Entire Treatment Period (up to Week 52) (Non-responder Imputation)

Exploratory

Time frame:
up to 52 weeks
Reported as:
Number · percentage of participants
Number and Percentage of Patients With Minimal Disease Activity Response by Visit in Entire Treatment Period (up to Week 52) (Non-responder Imputation)
percentage of participantsGroup 1Group 2Group 3Group 4Group 5
week 10.97————
week 1636.3669.7025.9344.7826.47
week 5226.2142.0014.2926.213.85
Other pre-specifiedNumber and Percentage of Patients With PASI75, PASI90 and PASI100 Response by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)

Exploratory

Time frame:
up to 52 weeks
Reported as:
Number · percentage of participants
Number and Percentage of Patients With PASI75, PASI90 and PASI100 Response by Visit - in Entire Treatment Period (up to Week 52) (Non-responder Imputation)
percentage of participantsGroup 1Group 2Group 3Group 4Group 5
PASI75 - week 18.867.511.768.434.65
PASI90 - week 11.27—2.941.21
PASI100 - week 1————2.33
PASI75 - week 1664.5680.0038.2454.2216.28
PASI90 - week 1649.3760.0017.6536.149.30
PASI100 - week 1625.3237.50—18.072.33
PASI75 - week 5267.0977.5052.9459.0453.49
PASI90- week 5248.1067.5035.2946.9944.19
PASI100 - week 5231.6555.0026.4737.3532.56

Adverse events

Collected over Adverse events (AE) were collected from first dose of study treatment until end of study treatment up to maximum duration of 52 weeks plus 12 weeks follow up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab 300mg0/191 (0%)15/191 (7.9%)66/191 (34.6%)
Secukinumab 150mg0/103 (0%)4/103 (3.9%)35/103 (34%)
Placebo1/52 (1.9%)3/52 (5.8%)12/52 (23.1%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventSecukinumab 300mgSecukinumab 150mgPlacebo
Cardiac arrestCardiac disorders0/1910/1031/52
Abdominal painGastrointestinal disorders0/1910/1031/52
DiarrhoeaGastrointestinal disorders0/1910/1031/52
Atypical pneumoniaInfections and infestations0/1910/1031/52
Ischaemic strokeNervous system disorders0/1910/1031/52
Myocardial infarctionCardiac disorders0/1911/1030/52
Meningitis asepticInfections and infestations0/1911/1030/52
Lower limb fractureInjury, poisoning and procedural complications0/1911/1030/52
SyncopeNervous system disorders1/1911/1030/52
AsthmaRespiratory, thoracic and mediastinal disorders1/1911/1030/52
Most frequent other events
Showing 10 of 12
Most frequent other events
EventSecukinumab 300mgSecukinumab 150mgPlacebo
Back painMusculoskeletal and connective tissue disorders10/1918/1038/52
Upper respiratory tract infectionInfections and infestations26/1916/1031/52
SinusitisInfections and infestations8/1913/1034/52
ArthralgiaMusculoskeletal and connective tissue disorders9/1913/1034/52
DiarrhoeaGastrointestinal disorders11/1917/1032/52
NasopharyngitisInfections and infestations6/1916/1031/52
Psoriatic arthropathyMusculoskeletal and connective tissue disorders3/1916/1030/52
HypertensionVascular disorders8/1916/1030/52
Musculoskeletal painMusculoskeletal and connective tissue disorders6/1911/1033/52
Pain in extremityMusculoskeletal and connective tissue disorders3/1915/1033/52

Baseline characteristics

Randomized Set

Age, Continuous
Age, Continuous(years)Group 1Group 2Group 3Total
Mean51.9 ± 12.5651.3 ± 14.5853.1 ± 12.6752.2 ± 80.86
Age, Customized
Age, Customized(Participants)Group 1Group 2Group 3Total
≥18-<402020848
≥40-<65656135161
≥65-<751418941
≥754408
Sex: Female, Male
Sex: Female, Male(Participants)Group 1Group 2Group 3Total
Female504729126
Male535623132
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1Group 2Group 3Total
Asian910120
Black2237
Caucasian888845221
Native American0112
Other2024
Pacific Islander1102
Unknown1102
08

Study locations

58 sites
  • Novartis Investigative Site
    Birmingham, Alabama 35205, United States
  • Novartis Investigative Site
    Little Rock, Arkansas 72205, United States
  • Novartis Investigative Site
    El Cajon, California 92020, United States
  • Novartis Investigative Site
    Fountain Valley, California 92708, United States
  • Novartis Investigative Site
    La Jolla, California 92093, United States
  • Novartis Investigative Site
    La Mesa, California 91942, United States
  • Novartis Investigative Site
    Upland, California 91786, United States
  • Novartis Investigative Site
    Aventura, Florida 33180, United States
  • Novartis Investigative Site
    Clearwater, Florida 33765, United States
  • Novartis Investigative Site
    DeBary, Florida 32713, United States
  • Novartis Investigative Site
    Jacksonville, Florida 32207, United States
  • Novartis Investigative Site
    North Naples, Florida 34102, United States
  • Novartis Investigative Site
    Palm Harbor, Florida 34684, United States
  • Novartis Investigative Site
    Pensacola, Florida 32514, United States
  • Novartis Investigative Site
    Plantation, Florida 33324, United States
  • Novartis Investigative Site
    Sarasota, Florida 34239, United States
  • Novartis Investigative Site
    Tampa, Florida 33609, United States
  • Novartis Investigative Site
    Tampa, Florida 33613, United States
  • Novartis Investigative Site
    Duluth, Georgia 30096, United States
  • Novartis Investigative Site
    Baltimore, Maryland 21224, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02115, United States
  • Novartis Investigative Site
    Worcester, Massachusetts 01655, United States
  • Novartis Investigative Site
    Battle Creek, Michigan 49015, United States
  • Novartis Investigative Site
    Kalamazoo, Michigan 49008, United States
  • Novartis Investigative Site
    Eagan, Minnesota 55121, United States
  • Novartis Investigative Site
    Lincoln, Nebraska 68516, United States
  • Novartis Investigative Site
    Las Vegas, Nevada 89106, United States
  • Novartis Investigative Site
    Ridgewood, New Jersey 07450, United States
  • Novartis Investigative Site
    Summit, New Jersey 07901, United States
  • Novartis Investigative Site
    Albany, New York 12206, United States
  • Novartis Investigative Site
    Brooklyn, New York 11201, United States
  • Novartis Investigative Site
    Lake Success, New York 11402, United States
  • Novartis Investigative Site
    Orchard Park, New York 14127, United States
  • Novartis Investigative Site
    Potsdam, New York 13676, United States
  • Novartis Investigative Site
    Saranac Lake, New York 12983, United States
  • Novartis Investigative Site
    Charlotte, North Carolina 28226, United States
  • Novartis Investigative Site
    Greensboro, North Carolina 27408, United States
  • Novartis Investigative Site
    New Bern, North Carolina 28562, United States
  • Novartis Investigative Site
    Marion, Ohio 43302, United States
  • Novartis Investigative Site
    Perrysburg, Ohio 43551, United States
  • Novartis Investigative Site
    Duncansville, Pennsylvania 16635, United States
  • Novartis Investigative Site
    Philadelphia, Pennsylvania 19104, United States
  • Novartis Investigative Site
    Charleston, South Carolina 29460, United States
  • Novartis Investigative Site
    Greenville, South Carolina 29601, United States
  • Novartis Investigative Site
    Orangeburg, South Carolina 29118-2475, United States
  • Novartis Investigative Site
    Jackson, Tennessee 38305, United States
  • Novartis Investigative Site
    Arlington, Texas 76014, United States
  • Novartis Investigative Site
    Arlington, Texas 77373, United States
  • Novartis Investigative Site
    Austin, Texas 78731, United States
  • Novartis Investigative Site
    Dallas, Texas 75231, United States
  • Novartis Investigative Site
    Dallas, Texas 75246, United States
  • Novartis Investigative Site
    Houston, Texas 77074, United States
  • Novartis Investigative Site
    Mesquite, Texas 75150, United States
  • Novartis Investigative Site
    San Antonio, Texas 78229, United States
  • Novartis Investigative Site
    Salt Lake City, Utah 84132, United States
  • Novartis Investigative Site
    Seattle, Washington 98122, United States
  • Novartis Investigative Site
    Spokane, Washington 99204, United States
  • Novartis Investigative Site
    Santurce, 00909, Puerto Rico
09

References and documents

Publications

  • Nguyen T, Churchill M, Levin R, Valenzuela G, Merola JF, Ogdie A, Orbai AM, Scher JU, Kavanaugh A, Kianifard F, Rollins C, Calheiros R, Chambenoit O. Secukinumab in United States Biologic-Naive Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study. J Rheumatol. 2022 Aug;49(8):894-902. doi: 10.3899/jrheum.210912. Epub 2022 Apr 15. PubMed 35428722 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Dec 2018, 29 months.

Results were first posted in Jan 2021, 2 years 1 month after primary completion. A results delay was requested in Oct 2019.

Of 33 phase 4 interventional studies under Arthritis, Psoriatic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 37. This study's 29 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2016
First posted
Jun 14, 2016
StartActual
Jun 27, 2016
Primary completionActual
Dec 5, 2018
CompletionActual
Dec 5, 2018
Results delay requested
Oct 2, 2019
Results first posted
Jan 28, 2021
Last update
Oct 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02798211
Responsible party
Sponsor
First posted
Jun 14, 2016
Start date
Jun 27, 2016
Primary completion
Dec 5, 2018
Completion
Dec 5, 2018
Results posted
Jan 28, 2021
Last update
Oct 7, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion